

## M&A Lab

December 03, 2008

### ZANDU - EMAMI HOSTILE TURNED FRIENDLY M&A DEAL DISSECTED

Dear All,

Recently Emami Limited (“**Emami**”), an Indian public company, entered into a share purchase agreement with the members of Parikh family, the co-promoters of Zandu Pharmaceuticals Works Limited (“**Zandu**”), an Indian listed company, and their associates for acquiring 18.18% in Zandu, thereby increasing their shareholding to 70.34% in Zandu. However, prior to the aforesaid friendly acquisition by Emami, Zandu and the Parikh family went into a dispute over Emami’s acquisition of approximately 23.62% from the Vaidya family, the other co-promoters of Zandu. The Parikh family invoked certain takeover defenses to prevent Emami from overthrowing the incumbent management of Zandu, which at the time of acquisition of shares by Emami rested in the hands of the Parikh family. What started as a hostile takeover attempt by Emami, ended as a friendly takeover on account of the compromise between Emami and Parikh family. It would be interesting to analyze the key securities and corporate law issues in this much talked about M&A deal.

For a detailed analysis of the legal issues, [please click here for the document](#).

As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative.

– Shikhar Kacker, Sadia Ashraf & Nishchal Joshipura  
You can direct your queries or comments to Team M&A

### DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

## Research Papers

### Global Capability Centers

May 27, 2025

### Fintech

May 05, 2025

### Medical Device Industry in India

April 28, 2025

## Research Articles

### 2025 Watchlist: Life Sciences Sector India

April 04, 2025

### Re-Evaluating Press Note 3 Of 2020: Should India’s Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

### INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

## Audio

### CCI's Deal Value Test

February 22, 2025

### Securities Market Regulator's Continued Quest Against “Unfiltered” Financial Advice

December 18, 2024

### Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

## NDA Connect

Connect with us at events, conferences and seminars.

## NDA Hotline

[Click here to view Hotline archives.](#)

## Video

### Vyapak Desai speaking on the danger of deepfakes | Legally Speaking with Tarun Nangia | NewsX

April 01, 2025

**SIAC 2025 Rules: Key changes &  
Implications**

February 18, 2025

